Details for New Drug Application (NDA): 208663
✉ Email this page to a colleague
NDA 208663 describes ETHACRYNATE SODIUM, which is a drug marketed by Endo Operations, Mylan Institutional, Sterimax, and Zydus Pharms, and is included in four NDAs. It is available from five suppliers. Additional details are available on the ETHACRYNATE SODIUM profile page.
The generic ingredient in ETHACRYNATE SODIUM is ethacrynate sodium. There are three drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the ethacrynate sodium profile page.
The generic ingredient in ETHACRYNATE SODIUM is ethacrynate sodium. There are three drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the ethacrynate sodium profile page.
Summary for 208663
| Tradename: | ETHACRYNATE SODIUM |
| Applicant: | Sterimax |
| Ingredient: | ethacrynate sodium |
| Patents: | 0 |
Pharmacology for NDA: 208663
| Physiological Effect | Increased Diuresis at Loop of Henle |
Suppliers and Packaging for NDA: 208663
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| ETHACRYNATE SODIUM | ethacrynate sodium | INJECTABLE;INJECTION | 208663 | ANDA | Leading Pharma, LLC | 69315-701 | 69315-701-50 | 1 VIAL, SINGLE-DOSE in 1 CARTON (69315-701-50) / 50 mL in 1 VIAL, SINGLE-DOSE |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | EQ 50MG BASE/VIAL | ||||
| Approval Date: | Jun 9, 2020 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
